Key Highlights
- Karyopharm Therapeutics filed an sNDA for Accelerated Approval of XPOVIO in combination with ruxolitinib for myelofibrosis.
- The filing cites Phase 3 SENTRY results showing spleen Volume reduction and potential disease modification.
- The submission includes a Priority Review request.
- An FDA filing decision is anticipated in the final quarter of 2026.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed an sNDA for accelerated approval of XPOVIO in combination with ruxolitinib for myelofibrosis, citing Phase 3 SENTRY results that demonstrated spleen volume reduction and potential disease modification.
What Happened
The submission includes a Priority Review request, with an FDA filing decision anticipated in the final quarter of 2026.
Market Reaction
The disclosed information does not include stock price or trading data for Karyopharm Therapeutics following the sNDA filing.
Outlook
The FDA's filing decision, anticipated in the fourth quarter of 2026, along with the outcome of the Priority Review request, represents the next major disclosed milestone for XPOVIO in myelofibrosis.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.